Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood
Hochhaus, Andreas A; Saglio, Giuseppe G; Larson, Richard A RA; Kim, Dong-Wook DW; Etienne, Gabriel G; Rosti, Gianantonio G; De Souza, Carmino C; Kurokawa, Mineo M; Kalaycio, Matt E ME; Hoenekopp, Albert A; Fan, Xiaolin X; Shou, Yaping Y; Kantarjian, Hagop M HM; Hughes, Timothy P TP